Regeneron Pharmaceuticals (REGN) Q1 2026 Earnings
Regeneron Pharmaceuticals reported Q1 2026 revenue of $3.6B (+19.0% YoY), beat analyst consensus of $3.5B by $122.0M. Diluted EPS came in at $9.47 (+15.2% YoY), beat the $8.91 consensus by $0.56. Regeneron Pharmaceuticals reports across 4 business segments, led by Ophthalmology, Immunology & Inflammation, and Oncology.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Regeneron Pharmaceuticals's Q1 2026 earnings report.
Regeneron Pharmaceuticals (REGN) reported Q1 2026 earnings on April 29, 2026 before market open.
Regeneron Pharmaceuticals reported revenue of $3.6B and diluted EPS of $9.47 for Q1 2026.
Revenue beat the consensus estimate of $3.5B by $122.0M. EPS beat the consensus estimate of $8.91 by $0.56.
Compared to the same quarter a year prior, revenue grew 19.0% from $3.0B a year earlier and diluted EPS grew 15.2% from $8.22.
You can read the 8-K earnings release (0000872589-26-000014) and the 10-Q periodic report (0000872589-26-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.